A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
← catalyst calendarSponsored by Neurocrine Biosciences (industry) · NBIX — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
73actual
Sites
13
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-20 | actual | When the study began enrolling |
| Primary completion | 2025-07-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-11 | actual | The whole study's end, after follow-up |
| First posted | 2024-02-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Major Depressive Disorder
Interventions
- Drug: NBI-1070770
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score from Baseline to Day 5
measured Baseline, Day 5
Permalink · NBIX's whole pipeline · Catalyst calendar · Every registered study · What changed